menu
    • menu

    Company profile for ANeuroTech

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ANeuroTech, based in Alken, Belgium, is a leader in the development of innovative mental health treatments with minimal or no side effects. The company is in late-stage clinical development of its lead asset, ANT-01, an adjunctive anti-depression drug which has been shown in late-stage clinical trials to improve depression remission rates and have a positive impact on cognitive function, with an excellent safety profile. ANeur...
    ANeuroTech, based in Alken, Belgium, is a leader in the development of innovative mental health treatments with minimal or no side effects. The company is in late-stage clinical development of its lead asset, ANT-01, an adjunctive anti-depression drug which has been shown in late-stage clinical trials to improve depression remission rates and have a positive impact on cognitive function, with an excellent safety profile. ANeuroTech was founded by CEO, Dr Erik Buntinx, an experienced clinician, key opinion leader and principal investigator on clinical trials for a number of CNS drugs including Spravato (esketamine).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ANeuroTechBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Alkerstraat 30A, 3570 Alken
    Telephone
    Telephone
    + 32 11 94 91 15
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aneurotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ANeuroTech publishes Phase IIIa data for ANT-01
    ANeuroTech publishes Phase IIIa data for ANT-01

    31 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/01/31/2820700/0/en/ANeuroTech-publishes-Phase-IIIa-data-for-ANT-01-an-adjunctive-anti-depression-drug-in-Personalized-Medicine-in-Psychiatry.html

    GLOBENEWSWIRE
    31 Jan 2024
    Share Share
    ANeuroTech receives FDA approval for Phase IIIb MDD drug trial
    ANeuroTech receives FDA approval for Phase IIIb MDD drug trial

    06 Jun 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/fda-ind-aneurotech-mdd-drug/

    CLINICAL TRIALS ARENA
    06 Jun 2023
    Share Share
    ANeuroTech receives IND approval from the FDA for ANT-01
    ANeuroTech receives IND approval from the FDA for ANT-01

    05 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/05/2681798/0/en/ANeuroTech-receives-IND-approval-from-the-FDA-for-pivotal-Phase-IIIB-trial-of-adjunctive-anti-depression-drug-ANT-01.html

    GLOBENEWSWIRE
    05 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search